following a full submission
elbasvir-grazoprevir (Zepatier®) is accepted for use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis C (CHC) in adults. (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not recommended in patients infected with these genotypes).
In patients with genotype 1a, 1b or 4, elbasvir-grazoprevir significantly increased sustained virologic suppression compared with a regimen containing a non-structural protein 5B (NS5B) inhibitor, an interferon and ribavirin.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of elbasvir-grazoprevir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice358KB (PDF)
Medicine details
- Medicine name:
- elbasvir-grazoprevir (Zepatier)
- SMC ID:
- 1203/17
- Indication:
- Treatment of chronic hepatitis C (CHC) in adults. (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not recommended in patients infected with these genotypes).
- Pharmaceutical company
- MSD
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 16 January 2017